OSTEOGRAF/N-300

K981182 · Ceramed Dental, LLC · LYC · Jul 2, 1998 · Dental

Device Facts

• Record ID: K981182
• Device Name: OSTEOGRAF/N-300
• Applicant: Ceramed Dental, LLC
• Product Code: LYC · Dental
• Decision Date: Jul 2, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 872.3930
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The intended use of OsteoGraf/N-300 is for: - Treatment of infrabony periodontal defects. - Augmentation of bony defects of the alveolar ridge. - Filling of extraction sites. - Sinus elevation grafting.

Device Story

OsteoGraf/N-300 is a bovine-derived, natural, high-purity, radiopaque, polycrystalline hydroxylapatite bone graft material. It consists of anorganic, rounded, irregular-shaped particles sized 250-420 microns. Used by dental clinicians to fill or augment bone defects in the oral cavity, including periodontal defects, alveolar ridge augmentation, extraction sites, and sinus elevation. The material acts as a bone void filler to support bone regeneration. It is a passive implantable device; no electronic or software components are involved.

Clinical Evidence

No clinical data provided; substantial equivalence is based on material characterization, including X-ray diffraction and FTIR analysis confirming 100% hydroxylapatite composition and compliance with ASTM F1581.

Technological Characteristics

Material: 100% anorganic bovine-derived hydroxylapatite (Ca10(PO4)6(OH)2). Particle size: 250-420 microns. Conforms to ASTM F1581. Radiopaque. Passive implantable device.

Indications for Use

Indicated for patients requiring bone filling or augmentation in dental procedures, specifically for infrabony periodontal defects, alveolar ridge defects, extraction site filling, and sinus elevation grafting.

Regulatory Classification

Identification

Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.

Special Controls

*Classification.* (1) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)(2) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Bio-Oss

Submission Summary (Full Text)

{0}------------------------------------------------

## JUL 2 1998

# 510(k) SUMMARY

March 31, 1998

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990.

- 1. Submitter: CeraMed Dental, L.L.C. 12860 West Cedar Drive, Suite 110 Lakewood. CO 80228 [phone]
- 2. Device Name: OsteoGraf/N-300 Hydroxylapatite Classification Name: Endosseous implant for bone filling and/or augmentation
- 3. Predicate Device: Bio-Oss
- 4. Device Description: OsteoGraf/N-300 is a natural, high purity, radiopaque, polycrystalline form of hydroxylapatite. the major mineral phase of bone and dental enamel. It is manufactured as anorganic, rounded, irregular shaped bovine derived hydroxylapatite particles, sized at 250-420 microns.

### 5. Intended Use:

The intended use of OsteoGraf/N-300 is for:

- Treatment of infrabony periodontal defects. .
- Augmentation of bony defects of the alveolar ridge. ●
- Filling of extraction sites.
- Sinus elevation grafting ●

### Q. Comparison of Product Characteristics:

OsteoGraf/N-300 consists of 100% anorganic hydroxylapatite, Ca.o(PO2), OHz.

X-ray diffraction and infrared analysis (FTIR) show OsteoGraf/N-300 to be 100% hydroxylapatite. OsteoGraf/N-300 conforms to the requirements of ASTM standard #F1581, Composition of Anorganic Bone for Surgical Implants.

{1}------------------------------------------------

Image /page/1/Picture/2 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes forming its wing. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. The logo is simple and recognizable, representing the department's role in providing health and human services to the United States.

2 1998 .UL

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Mark Bowerman Manager, Quality Assurance/Regulatory Affairs CeraMed Dental L.L.C. 12860 West Cedar Drive Lakewood, Colorado 80228

Re : K981182 Trade Name: OsteoGraf®/N-300 Requlatory Class: Unclassified Product Code: LYC Dated: March 31, 1998 April 1, 1998 Received:

Dear Mr. Bowerman:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) requlation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of

{2}------------------------------------------------

Page 2 - Mr. Bowerman

the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diaqnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to Other general premarket notification" (21 CFR 807.97). information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours

Timothy A. Ulatowski

Timothy A Ulatows Directo Division of Dental, Infection Control, and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Page 1 of 1

K981182 510(k) Number (if known):

OsteoGraf/N-300 Device Name:

Indications For Use:

The intended use of OsteoGraf/N-300 1s for:

- Treatment of infrabony periodontal defects. -
- Augmentation of bony defects of the alveolar ridge .. -
- Filling of extraction sites.
- Sinus elevation grafting. ﺴﻪ

(PLEASE DO NOT VIRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Conc irrence of CDRH, Office of Device Evaluation (ODE)

Gerald Shipps
(Division Sign-Off)

(Division Sign-Off) Division of Dental, Infection Control, and General Hospital Devices 27 510(k) Number .

**Prescription Use**
(Per 21 CFR 801.109) √

OR

Over-The-Counter Use_

(Optional Formal 1-2-96)